Silence Therapeutics welcomes treatment trial progress at Quark Pharmaceuticals

09:52 11/07/2018
StockMarketWire.com - Silence Therapeutics welcomed news that Quark Pharmaceuticals had dosed its first patient in a third-phase clinical trial of a treatment for acute kidney injury following cardiac surgery.

Quark held a license to Silence's chemical modification technology and Silence was eligible to receive payments from Quark.

The payments were either 1.5%-4% royalties from Quark plus milestones, or 15% of the clinical, regulatory and commercial milestone payments and royalties received by Quark from its partner Novartis.

At 9:52am: (LON:SLN) Silence Therapeutics PLC share price was 0p at 156p



Story provided by StockMarketWire.com

Forex

Commodities

What the Papers Say

telegraph financial times daily mail daily express independent times
10:01 Sports Direct profits tumble as bet on...
source: The Daily Mail
09:59 Pound hits 10-month low as UK retail sales...
source: The Guardian
09:54 Why do more than half of us think...
source: The Daily Mail
09:52 Buyers misled into using estate agents'...
source: The Daily Mail
09:52 Sports Direct profits tumble as tycoon...
source: The Daily Mail
09:41 Pound hits 10-month low as UK retail sales...
source: The Guardian
09:38 ‘I couldn't pick up my prepaid...
source: The Daily Mail
09:35 The dividend hero shares with yields as...
source: The Daily Mail
09:34 Pound dips below $1.30 for first time in...
source: FT.com
09:24 Chinese yuan hits one-year low as trade...
source: The Guardian
[more ...]